A phase I trial of combination of ublituximab + TGR-1202 + bendamustine in patients with advanced Diffuse Large B-Cell Lymphoma (DLBCL) and follicular lymphoma

Trial Profile

A phase I trial of combination of ublituximab + TGR-1202 + bendamustine in patients with advanced Diffuse Large B-Cell Lymphoma (DLBCL) and follicular lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Bendamustine (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Jun 2017 Results published in a TG Therapeutics media release.
    • 26 Jun 2017 According to a TG Therapeutics media release, data from this trial was presented at the 22nd European Hematology Association (EHA) Annual Congress.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top